NCT00368797已完成2 期
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease.
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 125
- 试验地点
- 7
- 主要终点
- Primary efficacy parameter: ulcer healing.
研究概览
简要总结
This study is a double-blind study to evaluate the efficacy and safety of NV1FGF, a pCOR plasmid constructed by inserting the gene coding for the FGF compared to placebo in patients with severe Peripheral Arterial Occlusive Disease, Fontaine's stage IV. The efficacy was assessed by the complete healing of at least one ulcer in the treated limb, 25 week post-baseline and secondary by the rate of amputation and death.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Outpatients with severe Peripheral Artery Occlusive Disease defined as Rutherford's Grade III, category 5 or 6, or Fontaine's stage IV.
- •Trophic lesions with no signs of healing (no reduction in ulcer size or depth) for at least 2 weeks prior to first study treatment administration (Day 1).
- •Patients with objective evidence of peripheral vascular disease (resting ankle pressure < 70 mmHg and/or toe pressure < 50 mmHg, and/or resting ankle-brachial index (ABI) < 0.4 and/or resting toe-brachial index (TBI) < 0.3 and/or metatarsal pulse volume recording (PVR) flat or barely pulsatile) in the diseased limb on two consecutive examinations performed at least 1 week apart.
- •Demonstration or documentation (historical data not older than 6 months prior to first study treatment administration) of total occlusion of the affected limb of one or more of the iliac, superficial femoral, popliteal and/or one or more infrapopliteal arteries as assessed by angiography.
- •Life expectancy > 6 months from the first study treatment administration.
- •Poor/not candidates for revascularization (patients suitable for revascularization but with a high risk of failure/ amputation/ or patients not suitable for revascularization).
排除标准
- •Previous or current history of malignant disease. Patients who had successful tumor resection or radio-chemotherapy more than 5 years prior to inclusion in the study and no recurrence will be allowed for inclusion.
- •Suspicion of malignant disease (abnormal X ray,positive. stool hemoccult, positive Prostate Specific Antigen , abnormal mammography, papanicolaou smear of Class IV or Class V characterization.
- •Lower extremity surgery : bypass/angioplasty of the leg to be treated within 2 months prior to the first administration of study treatment (Day 1).
- •Active proliferative retinopathy.
- •Buerger's disease
结局指标
主要结局
Primary efficacy parameter: ulcer healing.
Ulcers will be evaluated at each visit primarily by collecting quantitative and qualitative information.
次要结局
- Hemodynamic parameters:ABI, TcPO2
- Pain
- Amputation (Date of amputation, Indication for amputation, amputation level (minor and major)
- Death
研究者
研究点 (7)
Loading locations...
相似试验
已完成
2 期
Dose-finding, Safety and Efficacy Study of NV1FGF in Patients With Intermittent ClaudicationPeripheral Arterial Occlusive DiseaseNCT01157871Sanofi36
终止
1 期
A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19SARS-CoV-2 InfectionNCT04582318NGM Biopharmaceuticals, Inc16
进行中（未招募）
1 期
A Study of GC012F Injection in Subjects With Refractory Systemic Lupus ErythematosusNCT06530849Gracell Biotechnologies (Shanghai) Co., Ltd.20
已完成
2 期
NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHDAttention Deficit Disorder With HyperactivityNCT00557011New River Pharmaceuticals52
已完成
2 期
A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisNCT01281631Neuraltus Pharmaceuticals, Inc.136